Lung-resident antibacterial heterotypic immunity
Lung-resident antibacterial heterotypic immunity
批准号:
10646277
负责人:
JOSEPH P MIZGERD
金额:
$46.73万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2024-06-30
关键词:
AddressAdultAlveolarAlveolusAnatomyAnti-Bacterial AgentsAntigen PresentationAntigen Presentation PathwayBiologyBlack raceBlocking AntibodiesCD4 Positive T LymphocytesCD40 AntigensCell LineCell SeparationCellsCellular biologyChildColorDataDepositionDisparateElementsEpithelial CellsEpitheliumFosteringFutureGene Expression ProfilingGenesImmuneImmunityImmunofluorescence ImmunologicImmunologicsImmunologyInfectionInflammatoryInhalationKineticsLightLobeLower respiratory tract structureLungLymphocyteMicrobeMicroscopyMolecularMusPD-L1 blockadePatternPhysiologicalPhysiologyPneumococcal PneumoniaPneumoniaResolutionRespiratory Tract InfectionsRoleSignal TransductionStructureStructure of parenchyma of lungSupporting CellT memory cellT-LymphocyteTNFRSF5 geneTestingTissuesTransgenesType II Epithelial Receptor Celladaptive immune responseadaptive immunityalveolar epitheliumantimicrobialcell growth regulationcell typeconditional mutantforgivenessimmune resistanceimmunoreactioninsightlung injurymorphometrynovelpreventprogrammed cell death ligand 1respiratorysegregationtissue resident memory T celltranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The proposed studies will elucidate cellular and molecular mechanisms that organize the activities, fate, and
tissue localizations of CD4+ T cells in the lungs. CD4+ T cells are instructed by antigen presentation from
MHC-II and costimulatory or checkpoint molecules. Our preliminary data reveal that MHC-II is widely
expressed by lung epithelial cells, and dynamically regulated during and after resolution of pneumococcal
pneumonia. Furthermore, we observe that distinct sub-types of lung epithelial cells express different patterns of
costimulatory and checkpoint molecules. We propose that epithelial cell MHC-II pairs with cell-type-specific
expression of costimulatory and checkpoint molecules to appropriately instruct CD4+ T cells, localizing CD4+ T
cell activities and all aspects of adaptive immunity that depend on lung CD4+ T cells near more forgiving
regions (conducting airways) and away from more fragile and demanding elements (alveoli), to increase
immune resistance while diminishing lung injury. Our central hypothesis is that MHC-II on the lung epithelium
drives adaptive immunity toward the conducting airways and away from the alveoli, to be tested by pursuing
the following specific aims: (1) Test the hypothesis that pulmonary epithelial cells direct the anatomical
segregation of CD4+ T cells in the lung. This will be accomplished using multiple microscopy approaches to
document the regional kinetics and epithelial interactions of CD4+ cell expansion and contraction during and
after pneumonia, RNAseq of epithelial cells that are bright vs. dim for MHC-II, and conditional mutation of
MHC-II throughout all the lung epithelium. (2) Test the hypothesis that alveolar epithelial type II cells use MHC-
II plus PD-L1 to limit inflammatory lung injury. This will be accomplished using PD-L1 blockade, conditional
mutation of MHC-II in alveolar epithelial type II cells, and RNAseq of disparate classes of type II cells with
distinct patterns of MHC-II and checkpoint molecules. (3) Test the hypothesis that airway club cells and
multiciliated cells use MHC-II plus CD40 to bolster antimicrobial defense. This will be accomplished using
conditional mutation of MHC-II or of CD40 in both club cells and multiciliated cells. Altogether, the studies will
reveal whether and how lung epithelial cells orchestrate CD4+ T cell activities during pneumonia and
determine the TRM cell niche after resolution of infection. Results will identify naturally acquired immune
mechanisms that prevent pneumonia in older children and young healthy adults, provide insight into antigen
presentation pathways in the lung, and elucidate roles of checkpoint and costimulatory molecules in directing
lung CD4+ T cell biology.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pone.0179797
发表时间:
2017
期刊:
PloS one
影响因子:
3.7
作者:
[Kozlowski E, Wasserman GA, Morgan M, O'Carroll D, Ramirez NP, Gummuluru S, Rah JY, Gower AC, Ieong M, Quinton LJ, Mizgerd JP, Jones MR]
通讯作者:
Jones MR
DOI:
10.1097/mcp.0000000000000365
发表时间:
2017-05
期刊:
Current opinion in pulmonary medicine
影响因子:
3.3
作者:
[Mizgerd JP]
通讯作者:
Mizgerd JP
Pulmonary pathophysiology sub-phenotypes of pneumonia
-
批准号:10559704
-
项目类别:
-
资助金额:$82.3万
-
财政年份:2022
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Pulmonary pathophysiology sub-phenotypes of pneumonia
-
批准号:10446020
-
项目类别:
-
资助金额:$85.63万
-
财政年份:2022
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Pneumonia Biology
-
批准号:10543425
-
项目类别:
-
资助金额:$83.88万
-
财政年份:2017
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Pneumonia Biology
-
批准号:10225230
-
项目类别:
-
资助金额:$71.65万
-
财政年份:2017
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Pneumonia Biology
-
批准号:10320737
-
项目类别:
-
资助金额:$83.88万
-
财政年份:2017
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Lung-resident antibacterial heterotypic immunity
-
批准号:8986378
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2015
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Lung-resident antibacterial heterotypic immunity
-
批准号:10183144
-
项目类别:
-
资助金额:$48.12万
-
财政年份:2015
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Lung-resident antibacterial heterotypic immunity
-
批准号:9927559
-
项目类别:
-
资助金额:$48.72万
-
财政年份:2015
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Lung-resident antibacterial heterotypic immunity
-
批准号:9295936
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2015
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Lung-resident antibacterial heterotypic immunity
-
批准号:10447212
-
项目类别:
-
资助金额:$47.51万
-
财政年份:2015
-
负责人:JOSEPH P MIZGERD
-
依托单位:
2008 Biology of Acute Respiratory Infections Gordon Research Conference
-
批准号:7391507
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2007
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Regulation and function of STAT3 during pneumonia
-
批准号:6968007
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Regulation and function of STAT3 during pneumonia
-
批准号:7232094
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Cytokine-stimulated systemic defenses during pneumococcal pneumonia
-
批准号:8250351
-
项目类别:
-
资助金额:$41.02万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Cytokine-stimulated systemic defenses during pneumococcal pneumonia
-
批准号:8645682
-
项目类别:
-
资助金额:$39.8万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Cytokine-stimulated systemic defenses during pneumococcal pneumonia
-
批准号:8444454
-
项目类别:
-
资助金额:$38.95万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Regulation and function of STAT3 during pneumonia
-
批准号:7433135
-
项目类别:
-
资助金额:$38.52万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Regulation and function of STAT3 during pneumonia
-
批准号:7647919
-
项目类别:
-
资助金额:$38.52万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Cytokine-stimulated systemic defenses during pneumococcal pneumonia
-
批准号:8821645
-
项目类别:
-
资助金额:$39.72万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
Cytokine-stimulated systemic defenses during pneumococcal pneumonia
-
批准号:8107055
-
项目类别:
-
资助金额:$41.02万
-
财政年份:2005
-
负责人:JOSEPH P MIZGERD
-
依托单位:
海外基金